Terence Connelly, MD
Interventional Cardiology · Port Charlotte, FLNPI 1982617072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 388 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by Abbott at 28.6% of the total. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 388 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$861
- Amgen$634
- Philips North America LLC$538
- Medtronic$502
- Johnson & Johnson$485
- plus $3K from 29 others
Across 15 payments — averaging $9180.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$71K
- Astrazeneca UK Limited$32K
- Boehringer Ingelheim Pharma GmbH & Co.kg$23K
- Boehringer Ingelheim International GmbH$9K
- Amgen$3K
What the payments were for
- Food & beverage$8,45898%
- Education$2032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 98 | $2,477 |
| Boston Scientific | 39 | $861 |
| Amgen | 41 | $634 |
| Philips North America LLC | 9 | $538 |
| Medtronic(2 entities) | 17 | $502 |
| Johnson & Johnson | 23 | $485 |
| Novartis | 25 | $453 |
| Merck | 16 | $310 |
| Bayer | 11 | $260 |
| Pfizer | 14 | $258 |
| Boehringer Ingelheim | 17 | $247 |
| Astellas Pharma US Inc | 6 | $220 |
| E.r. Squibb & Sons, L.L.C. | 12 | $207 |
| Esperion Therapeutics, Inc. | 10 | $202 |
| Sanofi-aventis U.S. LLC | 8 | $160 |
| AstraZeneca | 10 | $134 |
| Atricure, Inc. | 1 | $116 |
| Regeneron Healthcare Solutions, Inc. | 5 | $68 |
| Heartflow, Inc. | 3 | $62 |
| Cvrx, Inc. | 2 | $61 |
| Bard Peripheral Vascular, Inc. | 2 | $60 |
| Scpharmaceuticals Inc. | 2 | $47 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $45 |
| Penumbra, Inc. | 3 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Biotronik Inc. | 1 | $27 |
| Vital Connect, Inc | 1 | $26 |
| Aegerion Pharmaceuticals, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
| Chiesi USA, Inc. | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,661 in reported general payments places this provider in the 50th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 502 | $581,608 |
| XareltoRivaroxaban | 188 | $226,430 |
| EntrestoSacubitril/Valsartan | 122 | $203,004 |
| Repatha SureclickEvolocumab | 101 | $130,044 |
| MultaqDronedarone Hcl | 42 | $68,973 |
| JardianceEmpagliflozin | 14 | $19,461 |
| Praluent PenAlirocumab | 18 | $16,335 |
| BrilintaTicagrelor | 19 | $16,261 |
| Metoprolol Succinate | 419 | $6,286 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $5,200 |
| Atorvastatin Calcium | 537 | $4,434 |
| Ezetimibe | 247 | $4,371 |
| Ranolazine ErRanolazine | 35 | $3,884 |
| Rosuvastatin Calcium | 263 | $3,859 |
| Losartan Potassium | 397 | $3,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $258 | $581,608502 claims |
| Johnson & JohnsonXarelto | $485 | $226,430188 claims |
| NovartisEntresto | $453 | $203,004122 claims |
| Sanofi-aventis U.S. LLCMultaq | $160 | $68,97342 claims |
| Boehringer IngelheimJardiance | $247 | $19,46114 claims |
| AstraZenecaBrilinta | $134 | $16,26119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Port Charlotte
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.